^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1821736

    i
    Other names: BI 1821736
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    Immunostimulant, Cell death stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov)
    P1, N=27, Suspended, Boehringer Ingelheim | Trial completion date: Nov 2025 --> Jan 2027 | Recruiting --> Suspended | Trial primary completion date: Nov 2024 --> Jan 2026
    Trial completion date • Trial suspension • Trial primary completion date • Metastases
    |
    BI 1821736
    over1year
    A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov)
    P1, N=27, Recruiting, Boehringer Ingelheim | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Jan 2026 --> Nov 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BI 1821736
    over1year
    A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov)
    P1, N=27, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2024 --> Jan 2026
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    BI 1821736